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Background: Diffuse myocardial fibrosis, and to a lesser extent global myocardial edema, are important processes
in heart disease which are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using
conventional late gadolinium enhancement (LGE) or T1-mapping. Measurement of the myocardial extracellular
volume fraction (ECV) circumvents factors that confound T1-weighted images or T1-maps. We hypothesized that
quantitative assessment of myocardial ECV would be clinically useful for detecting both focal and diffuse
myocardial abnormalities in a variety of common and uncommon heart diseases.
Methods: A total of 156 subjects were imaged including 62 with normal findings, 33 patients with chronic
myocardial infarction (MI), 33 with hypertrophic cardiomyopathy (HCM), 15 with non-ischemic dilated
cardiomyopathy (DCM), 7 with acute myocarditis, 4 with cardiac amyloidosis, and 2 with systemic capillary leak
syndrome (SCLS). Motion corrected ECV maps were generated automatically from T1-maps acquired pre- and post-
contrast calibrated by blood hematocrit. Abnormally-elevated ECV was defined as >2SD from the mean ECV in
individuals with normal findings. In HCM the size of regions of LGE was quantified as the region >2 SD from
remote.
Results: Mean ECV of 62 normal individuals was 25.4 ± 2.5% (m± SD), normal range 20.4%-30.4%. Mean ECV within
the core of chronic myocardial infarctions (without MVO) (N = 33) measured 68.5 ± 8.6% (p < 0.001 vs normal). In
HCM, the extent of abnormally elevated ECV correlated to the extent of LGE (r = 0.72, p < 0.001) but had a
systematically greater extent by ECV (mean difference 19 ± 7% of slice). Abnormally elevated ECV was identified in 4
of 16 patients with non-ischemic DCM (38.1 ± 1.9% (p < 0.001 vs normal) and LGE in the same slice appeared
“normal” in 2 of these 4 patients. Mean ECV values in other disease entities ranged 32-60% for cardiac amyloidosis
(N = 4), 40-41% for systemic capillary leak syndrome (N= 2), and 39-56% within abnormal regions affected by
myocarditis (N = 7).
Conclusions: ECV mapping appears promising to complement LGE imaging in cases of more homogenously
diffuse disease. The ability to display ECV maps in units that are physiologically intuitive and may be interpreted on
an absolute scale offers the potential for detection of diffuse disease and measurement of the extent and severity
of abnormal regions.
Keywords: Fibrosis, Edema, Gadolinium, Myocardial infarction, Hypertrophic cardiomyopathy, Dilated
cardiomyopathy, Myocarditis, Systemic capillary leak syndrome* Correspondence: kellmanp@nhlbi.nih.gov
1National Heart, Lung, and Blood Institute, National Institutes of Health,
Bethesda, MD, USA
Full list of author information is available at the end of the article
© 2012 Kellman et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kellman et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:64 Page 2 of 8
http://www.jcmr-online.com/content/14/1/64Background
Measurement of the extracellular volume fraction (ECV)
in the myocardium could provide a quantitative method
for assessing cardiomyopathies which may develop diffuse
fibrosis or edema. Diffuse myocardial fibrosis is difficult to
distinguish using late gadolinium enhancement (LGE)
since the myocardial signal intensity is deliberately nulled
to enhance the heterogeneity of abnormal myocardium
thus homogeneously diffuse tissue will be nearly isointense
and therefore globally “nulled” becoming indistinguishable
from normal tissue [1]. ECV relates directly to the tissue
distribution of most gadolinium-based contrast agents. A
number of recent studies [1-8] have demonstrated the po-
tential of ECV measurement. ECV maps are based on
measurement of the longitudinal relaxation time constant
(T1) both pre- and post-contrast, and are calibrated using
the value of hematocrit [9].
Previous studies have measured the ECV using manual
regions of interest drawn on T1-maps or by performing
a manual or semi-automatic image registration of T1-
maps. A fully automated method has been presented for
calculating pixel-wise ECV parametric maps (ref Part I).
The method included correction of respiratory and pa-
tient motion, and automatic segmentation.
The goal of this research was to evaluate the utility of
the automated method for producing a pixel-wise map
of ECV and to establish baseline quantitative values for
normal subjects. We hypothesized that measurement of
ECV, a physiological parameter directly related to the
tissue distribution of an extracellular gadolinium-based
contrast agent, would detect both focal and diffuse myo-
cardial abnormalities in a variety of common and un-
common diseases. We established a normal range in 62
subjects. Next, we tested the hypothesis that patients
with known regional abnormalities in the heart would
have regional abnormalities in ECV by imaging patients
with chronic myocardial infarctions and hypertrophic
cardiomyopathy. Finally, we assessed the myocardial
ECV in patients with diseases that might manifest with
more diffuse abnormalities such as amyloidosis, non-
ischemic dilated cardiomyopathy (DCM), and systemic
capillary leak syndrome (SCLS).
Methods
Human subject protocol
ECV imaging was performed between Sept 2009 and May
2011. This study was approved by the local Institutional
Review Boards of the National Heart, Lung, and Blood In-
stitute and Suburban Hospital, and all subjects gave writ-
ten informed consent to participate. Hematocrit was
measured from a venous blood sample drawn just prior to
the CMR study.
All patients were referred for CMR assessment of
known or suspected heart disease prospectively underwentECV imaging. For the purpose of this study, subjects were
included in this analysis based on the following criteria.
Normal subjects (n= 62) were used to establish baseline
values of myocardial ECV. Normal subjects were defined
as patients who were without known significant systemic
illness, whose studies demonstrated normal biventricular
systolic function, chamber size, and wall thickness, absent
significant valvular dysfunction, and lack of late gadolin-
ium enhancement. Subjects with hypertension or diabetes
were excluded from this group and their clinical character-
istics have been described (ref Part I). Chronic myocardial
infarction (MI) was defined as a region of increased signal
intensity on LGE that included the subendocardium that
was within a coronary territory, and occurring in a patient
with a clinical syndrome consistent with an acute coronary
syndrome at least 6 months prior to the scan. Myocarditis
was defined as a clinical syndrome established by the pres-
ence abnormal cardiac biomarkers (troponin I assay) in
the absence of coronary artery disease, with a regional wall
motion abnormality and increased signal intensity in the
corresponding region on T2-weighted images. The diag-
nosis of hypertrophic cardiomyopathy (HCM) was sup-
ported by left ventricular hypertrophy (wall thickness
>15 mm) in the absence of a clinical condition known to
cause hypertrophy. If wall thickness was 10-15 mm, one
or more additional criteria were required: (1) hypertrophy
in a recognizable pattern like that of apical-variant HCM;
(2) systolic anterior motion of the mitral valve with mitral
regurgitation; and (3) resting left ventricular outflow tract
obstruction. Cardiac amyloidosis was based on biopsy evi-
dence of amyloidosis or presence of a disease known to
cause cardiac amyloidosis (e.g. multiple myeloma). Nonis-
chemic dilated cardiomyopathy (DCM) was defined as glo-
bally reduced systolic function (ejection fraction <45%)
with an enlarged left ventricular chamber in the absence of
obstructive coronary artery disease. Chronic systemic capil-
lary leak syndrome (SCLS) was diagnosed according to
established criteria (persistent peripheral edema and
hypoalbuminemia in the absence of secondary causes) [10].
Imaging
ECV maps were derived from T1-maps acquired pre- and
post-contrast using the MOLLI method [11] calibrated by
blood hematocrit as described previously (ref Part I). The
approach incorporates correction of respiratory motion
that occurs due to insufficient breath-holding [12] and
due to patient movement between breath-holds. Addition-
ally, cine MRI of cardiac function and phase sensitive in-
version recovery (PSIR) late gadolinium enhancement
(LGE) imaging [13] was performed on all subjects.
Image and statistical analysis
The myocardium was manually segmented for ECV and
LGE measurements. In subjects with regions of abnormal
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of chronic MI, ECV values were measured in the central
core region of the MI.
The normal range of ECV values in the myocardium
was defined as mean± 2SD of ECV values in the normal
group, and pixels were assessed as abnormal in LGE
images for signal intensities greater than the mean + 2SD
in a normal region in the same image.
Group statistics were measured for subjects with
HCM (n= 33) and chronic MI (n = 33). ECV measure-
ments were made on subjects with non-ischemic DCM
(n= 15) and cardiac amyloidosis (n = 4) but groupTable 1 Patient characteristics
N Age (years) Male
(Mean
+/−SD)
Myocarditis 7 36.3+/−14.8 5
Nonischemic DCM 15 51.2+/−15.6 10
SCLS 2 53+/−11 0
Cardiac Amyloidosis 4 69+/−3.1 3
HCM 33 50.9+/−13.9 24
Chronic MI 33 57.3+/−9.5 27
Normal 62 43.6+/−17.4 30
156 99
Table 2 Patient characteristics (CMR measurements)
Left ventricular mas
N LVEF (%) LVEDV
(mL)
Myocarditis 7 56.2 167.2
+/−4.8 +/−26
Nonischemic DCM 15 41.2 226.7
+/−8.9 +/−61.9
SCLS 2 72.2 145.3
+/−4.7 +/−17.8
Cardiac Amyloidosis 4 48.8 139
+/−12.8 +/−45.4
HCM 33 61.8 163
+/−5.4 +/−33.1
Chronic MI 33 46.8 195.4
+/−14.2 +/−62
Normal 62 61.7 143.9
+/−5.9 +/−32.9
156
BMI = Body Mass Index, DCM=Dilated Cardiomyopathy, SCLS = Systemic Capillary L
LV = left ventricular, EF = ejection fraction, EDV= end-diastolic volume. Wall thicknes
wall thickness represents maximal diastolic wall thickness in any short axis slice.correlations to the size of LGE regions were not per-
formed in these entities due to the small numbers and
the diffuse nature of these processes.
The percentage of pixels with abnormally elevated
ECV (> 30.4%) was compared with the percentage of
enhanced pixels in LGE images that were greater than
mean + 2SD measured in a remote region that appeared
“normal”.
Data are presented as mean and standard deviation.
Differences between means were tested by the paired or
unpaired t-test, as appropriate. Statistical significance
was defined as p < 0.05.Gender




















89.6 106.5 57.2 8.2
+/−13.3 +/−20.9 +/−11.7 +/−2.2
103.5 145.4 66.7 8.9
+/−15.4 +/−42.8 +/−15.2 +/−2
75.7 79.5 42.2 6.7
+/−0.2 +/−2.5 +/−6.6 +/−0.4
71.1 146.8 75.6 12.4
+/−19 +/−44.3 +/−18.6 +/−1.8
83.8 169.4 86.7 19.1
+/−13.2 +/−73.2 +/−36.1 +/−6.2*
103.9 112.3 59.5 8.8
+/−33.9 +/−28.6 +/−14.8 +/−1.9
76.9 87.4 46.2 7.5
+/−12.2 +/−26.2 +/−9.5 +/−1.8
eak Syndrome, HCM=Hypertrophic Cardiomyopathy, MI =Myocardial Infarction,
s was measured in the basal anteroseptum in all conditions except HCM where
Figure 1 ECV values for normal myocardium (n= 62), focal
abnormalities in HCM (n= 33), and chronic MI (n = 33). Box and
whisker plots show median, 25 and 75 percentiles, and range.
Figure 3 Comparison of the percent of myocardium classified
as abnormal by ECV using a fixed threshold (ECV>30.4%) and
the percent of LGE>mean+2SD (measured in remote
“normal”). Linear fit (red) is%ECV= 1.07%LGE= 0.19.
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Demographics
Patient characteristics for each group are summarized in
Tables 1 and 2. The self described race/ethnicity of the
156 subjects was as follows: 117 white, 20 black or African
American, 14 Asian, and 5 Hispanic.ECV measurements in normal subjects
ECV measurements (Figure 1) were made in 62 normal
subjects that were LGE negative and appeared clinically
normal during independent clinical interpretation. Mean
ECV in normal individuals was 25.4± 2.5% (m±SD) yield-
ing a normal range for myocardial ECV of 20.4-30.4%. The
pre-contrast T1 was 964.6±35.3 ms yielding a normal
range 894 to 1035 ms.ECV measurements in abnormal studies
In the 33 patients with HCM, the percentage of myocar-
dium with elevated ECV correlated with the amount of
myocardium with abnormal LGE (R = 0.72, p < 0.001)
(Figure 2) and the amount of myocardium with abnor-
mal ECV systematically exceeded the amount of myocar-
dium with abnormal LGE (% ECV= 1.07%LGE+0.19,
Figure 3). HCM subjects had mean ECV values for pixels
above the normal range (Figure 1) equal to 35.7 ± 2.9%
(m± SD) (p < 0.001 vs normal). The mean ECV value of
“normal” pixels was 26.5 ± 1.3%. Myocardial ECV values
in HCM were more heterogeneous and had lower mean
value than for MI (p < 0.001, Figure 1).Figure 2 LGE and corresponding ECV map for subject with HCM. LGE
values > 30.4% fixed threshold (corresponding to the mean+ 2SD for myocECV values for chronic MI (n = 33) were equal to
68.5 ± 8.6% (p < 0.001 vs normal). There were no cases of
chronic MI with microvascular obstruction.
In patients with acute myocarditis (n = 7), all subjects
had focally elevated ECV> 30.4%. ECV values for sub-
jects with elevated ECV were 44 ± 6% and 26.4 ± 3%, in
focally elevated and remote regions, respectively.
There were 18 subjects with non-ischemic DCM, of
whom 3 did not have measurable ECV due to patient
movement between pre- and post-contrast acquisitions.
Regions of abnormally elevated ECV were identified in 4
of 16 patients with non-ischemic DCM and LGE in the
same slice appeared “normal” in 2 of these 4 patients.
ECV was 38.1 ± 1.9% (p < 0.001 vs normal) in the non-
ischemic DCM patients with elevated ECV.
There were 4 subjects with cardiac amyloidosis. The
ECV values for these subjects had mean values ranging
from 32 to 60% with an overall mean of 46 ± 12%.
In subjects with SCLS with abnormally elevated
ECV (n = 2), the ECV had a mean ECV of 41% with
global distribution throughout the heart. Further-
more, the mean pre-contrast T1 was 1145 ms, which
is abnormally long.values >mean+ 2SD measured in a “normal” region and ECV
ardium in a normal group) are classified as abnormal.
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ECV maps, T1-maps pre- and post-contrast, and corre-
sponding PSIR late gadolinium enhancement images are
shown in Figure 4 as examples of focal enhancement in-
cluding (a) chronic MI, (b) myocarditis, and (c) HCM.
Focal scar is readily detectable in both the conventional
late gadolinium enhancement and ECV maps with excel-
lent spatial agreement. In these figures, ECV maps and
T1-maps are displayed with a fixed window-level (ECV
from 0-100%, pre-contrast T1 from 0 to 2000 ms, and
post-contrast T1 from 300–700 ms), while PSIR LGE
images are displayed to null normal myocardium.
Note that the post-contrast T1-maps have a consider-
ably different appearance using a fixed scale due to the
variation of renal clearance of gadolinium, body compos-
ition and baseline T1, further emphasizing the difficulty of
directly using post-contrast T1 values alone without ECV
calculation. Elevated pre-contrast T1 is pronounced in the
subject with acute myocarditis (Figure 4(b)), which is
expected in a patient with myocardial edema. For thisFigure 4 Examples illustrating excellent agreement between LGE and
contrast T1-maps (top row), post-contrast T1-maps (2nd row), late gadoliniu
with: (a) chronic MI, (b) acute myocarditis, and (c) HCM.specific case of acute myocarditis the region correspond-
ing to signal enhancement on LGE had measured values
of T1pre/T1post/ECV=1249 ms/ 487 ms / 51%.
ECV maps in diseases with diffuse gadolinium
enhancement
Figure 5 contains examples with diffusely elevated ECV
for subjects with (a) non-ischemic dilated cardiomyopathy
(DCM), (b, c) cardiac amyloidosis, and (d) systemic capil-
lary leak syndrome (SCLS) [10]. In these more diffuse
cases it is difficult to distinguish abnormal from normal
regions using conventional late enhancement. Notably, the
ECV image provides quantitative characterization of myo-
cardium in physiologically intuitive units of measurement.
In 3 of these cases (Figure 5(a, c, d), the LGE is nulled rea-
sonably well on a global basis, thereby appearing normal.
For the DCM case (Figure 5(a)) values were T1pre/
T1post/ECV= 1103 ms/ 387 ms/ 37% in the septum and
1027 ms/426 ms/30% in the inferior wall. For the subject
with cardiac amyloidois (Figure 5(c)) measured valuesECV in cases of focal abnormalities in myocardial ECV. Pre-
m enhancement (3rd row), and ECV maps (bottom row) for patients
Figure 5 Examples illustrating cases with diffuse abnormalities in myocardial ECV which are challenging to assess with conventional
LGE. Pre-contrast T1-maps (top row), post-contrast T1-maps (2nd row), late gadolinium enhancement (3rd row), and ECV maps (bottom row) for
patients with various cardiomyopathies: (a) non-ischemic DCM with diffusely elevated ECV and normal appearing LGE, (b) cardiac amyloidosis
with “patchy” LGE enhancement, (c) cardiac amyloidosis with diffusely elevated ECV and globally nulled LGE, and (d) systemic capillary leak
syndrome (SCLS) with globally elevated ECV due to edema and normal LGE.
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subject with SCLS (Figure 5(d)) measured values were
T1pre/T1post/ECV= 1126 ms/496 ms/41%. In one subject
with cardiac amyloidosis (Figure 5(b)), the LGE image is
diffusely enhanced in the septal region but might be
interpreted as normal in the inferior wall which may be
nulled. For this case (Figure 5(b)) measured values were
T1pre/T1post/ECV= 1139 ms/351 ms/51% in the septum
and 1059 ms/394 ms/41% in the inferior wall (i.e., the
inferior wall appears normal by LGE but has abnormally
elevated ECV).
Discussion
The main finding of the study is that ECV-mapping can
quantitatively characterize myocardial tissue characteristics
over a broad range of myocardial diseases including patho-
physiological states with either focal and/or diffuse changes
in myocardial ECV. In cases of focal scar such as chronic
MI and focal edema and/or necrosis such as acute myocar-
ditis, ECV maps were in excellent agreement with LGE.
These cases were measured to provide a confirmation that
the ECV performs accurately in instances where the result-
ing enhancement is known and readily assessable. In cases
with patchy LGE such as HCM, the LGE is sufficientlyheterogeneous that it is possible to null normal appearing
regions of myocardium thus providing a baseline for detec-
tion of patches with late enhancement. In these cases, the
regions of elevated ECV correlated well with the regions of
LGE. In cases of HCM, it was possible to detect abnormal
tissue regions using a fixed threshold derived from statis-
tics of the normal group independent of the presence of
normal appearing regions within the slice of interest.
The current study presents quantitative myocardial ECV
measurements in the settings of chronic myocardial infarc-
tion, HCM, DCM, myocarditis, amyloidosis and SCLS.
Previous studies have measured myocardial ECV in aging
[6,7], chronic myocardial infarction [7,14], non-ischemic
cardiomyopathies in general [7] and in particular DCM [3],
aortic stenosis and HCM [2] and congenital heart disease
[5]. Our current results broadly agree with these prior
reports with regards to the magnitude of ECV in both focal
and diffuse myocardial disease. With the exception of
Ugander, et al. [7], all previous reports are based on region
of interest measurements performed in images that do not
permit visualization of the spatial extent of variations in
myocardial ECV. The methods of Ugander, et al., [7]
required time consuming and cumbersome manual post-
processing for motion correction. The current work, as a
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ings and presents results using a method for fully auto-
mated generation of ECV images in a clinically feasible
work flow.
As described previously (ref Part I), there are cases in
which patient movement resulted in the slices being sub-
stantially different in appearance despite the fact that the
same slice position was prescribed. Co-registration is by
design only capable of correcting for in-plane motion and
cannot compensate for through plane motion, although it
may appear to partially compensate. In other cases, it is
clear that the pre- and post-contrast images are at sub-
stantially different cardiac phases due to significant change
in heart rate, despite adjusting the trigger window. Both of
these factors could potentially be improved at the time of
acquisition by more careful inspection at the cost of a
more complicated workflow.
The ability to interpret lower quality ECV maps and not
mistake uncorrected motion artifacts or partial volume
border pixels for sub-endocardial or sub-epicardial fibrosis
is a residual and important issue. Motion related errors
occur both intra-series and between pre-and post-contrast
series. The correction of intra-series motion due to inad-
equate breath-holding was referred to as MOCO, whereas
the correction of subject motion between pre- and post-
contrast acquisition was referred to as co-registration. The
use of error maps based on residual errors in pixel-wise
T1-fitting provide a means of determining the MOCO
error, and may serve as a quality metric. In terms of co-
registration errors, the interpretation can be improved by
examining the pre-and post-contrast T1-maps for consist-
ent appearance of position and cardiac phase as a quality
control step. Furthermore, it is expected that the use of
ECV maps will be in conjunction with pre-contrast T1-
maps and conventional late gadolinium enhancement
images, and not interpreted independently. As such, the
ability to assess and quantify diffuse fibrosis in ECV
images should provide increased diagnostic confidence
since LGE image quality is generally excellent and will not
share the same artifacts.
The partial volume issue is not only important in
terms of the visual readout, but may introduce biases
into quantitative measurements which become particu-
larly significant in the context of more subtle diseases.
These effects are less problematic for globally diffuse
processes. One approach to reducing the bias in mea-
surements is to restrict the measurement to the mid-
wall region, although one must exercise caution for sub-
jects with thin walled myocardium or patients with thin
rims of subendocardial fibrosis. Blood pool contamin-
ation of the myocardium in border pixels can lead to
biases if included in the measurement, and in general
may contribute more significantly in subjects with thin
myocardial wall thickness. This might lead to anapparent elevated ECV in subjects with thin walls such
as healthy females or subjects with DCM, and thereby
might lead to an underestimation of the difference in
these populations with subjects that have hypertrophy
since thicker myocardium should have less error due to
partial volume at the borders.
Quantitative ECV pixel maps may have potential for
analysis of border zones around MI. However, caution
must be exercised in differentiating partial volume
effects from true pathophysiological mechanisms. Partial
volume effects affect the measurement of ECV by con-
tributing to larger variability in fine structures such as
subendocardial MI. Similar to LGE, the partial volume
“blurring” due to the slice thickness may contribute sig-
nificantly to the apparent border zone.
Despite these issues, ECV maps may be readily incor-
porated into the clinical workflow and may provide diag-
nostic information where other methods are limited. It
is not intended to replace existing methods such as LGE
which are excellent at depicting focal lesions, but rather
to be used in concert with other techniques. When ECV
is abnormally elevated, it may not be clear whether this
is due to fibrosis or edema which may be either diffuse
or focal. In such instances, pre-contrast T1 or T2 maps
[15], in addition to patient history and contextual im-
aging clues like signs of heart failure, may help to differ-
entiate these mechanisms. Finally, several cases were
presented for subjects with diffusely elevated LGE. These
demonstrate the proposed utility of ECV mapping in
cases which are frequently challenging to assess.
Limitations
The number of subjects is small for some of the sub-
groups in this study. In these cases, large scale studies
are needed to establish the clinical utility. In this study
which compared the percentage of abnormal tissue by
ECV measurement and LGE using mean+ 2SD thresh-
old, it was not possible to conclude which measurement
was more accurate. Estimates of both the mean and SD
in normal appearing LGE regions are generally subject
to being biased on the high side due to signal inhomo-
geneities, and in this case could explain the underesti-
mation by LGE using this type of thresholding.
Conclusions
ECV mapping appears promising to complement LGE
imaging in cases of more homogenously diffuse myo-
cardial disease states which affect the myocardial
extracellular space. The ability to display ECV maps
in quantitative and physiologically intuitive units that
may be interpreted on an absolute scale offers the po-
tential for simplified detection and measurement of
the extent and severity of abnormalities affecting the
myocardial ECV.
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